Thomas P. Conrads, PhD
Chief Scientific Officer
Gynecologic Cancer Center of Excellence
3289 Woodburn Rd
Suite 375
Annandale,
VA
USA
22003
Papers:
11 - Focused Plenary
Molecular profiling of tumors from stage I versus stage III/IV cancer patients: a prediction signature for metastasis in Gynecologic Oncology Group 8024
43 - Featured Poster
Identification of candidate circulating cisplatin resistance biomarkers from epithelial ovarian carcinoma cell secretomes
49 - Featured Poster
Pathogenesis of ARID1A-driven gynecologic cancer
52 - Featured Poster
Pharmacologic inhibition of the DNA damage response kinases ATR (ataxia telangiectasia and rad3 related) and ATM (ataxia telangiectasia mutated) broadly sensitizes diverse subtypes of gynecologic cancer cells to ionizing radiation
98 - Featured Poster
Phase I trial results of a folate receptor alpha-directed cancer vaccine (E39) in ovarian and endometrial cancer patients to prevent recurrence
229 - Poster Session A
Subcellular localization of AT-rich interactive domain1A protein expression is associated with survival in epithelial ovarian and peritoneal carcinoma
269 - Poster Session A
Enhanced gynecologic cancer cell killing through pharmacologic inhibition of the ataxia telangiectasia and Rad3-related kinase
295 - Poster Session A
Curated Ovarian Database-derived identification of genes predicting survival in primary serous epithelial ovarian cancer
306 - Poster Session A
Pharmacologic inhibition of polo-like kinase 1 enhances paclitaxel-based cell killing in taxol-resistant ovarian cancer cells
334 - Poster Session A
Proteomic profiling of stage I endometrial cancers: a signature of early-stage recurrence in GOG 8016
337 - Poster Session A
Proteomics of endometrial carcinogenesis: identification of candidates underlying disease pathogenesis
525 - Poster Session B
Correlation of survival-stratified proteomic and curated gene data reveal a three protein biomarker panel that predicts long-term survival of patients with primary epithelial ovarian cancer